- Novel aggregation-speciﬁc ﬂuorogen (TPE-TPP) has superior characteristics to Thioﬂavin T
- TPE-TPP monitors preﬁbrillar species of amyloidogenic proteins by ﬂuorescence polarization
- CLARIOstar microplate reader provides stable measurements, incubation and shaking platform
Table of contents
Highly ordered protein aggregates, termed amyloid ﬁbrils, are associated with a broad range of diseases, many of which are neurodegenerative, for example, Alzheimer’s and Parkinson’s. The transition from soluble, functional protein to insoluble amyloid ﬁbril occurs via a complex process involving the initial generation of highly dynamic early stage aggregates or preﬁbrillar species. Preﬁbrillar species (dimers, tetramers etc.) are proposed to play a key role in the cytotoxicity of amyloid ﬁbrils. Therefore, novel probes that have broad applicability in the detection of preﬁbrillar species of amyloidogenic proteins are actively being sought.
We have recently reported1 a novel broad-spectrum ﬂuorescent probe: (bis(triphenylphosphonium) tetraphenylethene (TPE-TPP)), with emission characteris tics that are eminently suited to monitoring preﬁbrillar aggregation of various protein species using various ﬂuorescence techniques. Herein, we describe our results for Fluorescence Polarisation (FP).
FP measures the rotation of molecules in solution, using plane polarised light. Generally, small ﬂuorophores such as TPE-TPP rotate quickly in water. When excited with polarised light, the individual molecules rotate randomly before emission. Their emitted light is depolarised and has a small FP value. If the ﬂuorophore is bound to a large protein the whole complex rotates slowly. The emitted light from the complex remains plane polarised and the FP value is large (Fig. 1).
This technique is well suited to study amyloid aggregation of proteins as the FP value is dependent on the increasing mass of the TPE-TPP/protein complex and less dependent on the ﬂuctuation of ﬂuorescence intensity caused by the inhomogeneity of the solution. In this study, the change in FP for TPE-TPP during the aggregation of reduced and carboxymethylated α-lactalbumin (RCM α-LA), RCM ĸ-casein and insulin, was examined.
Materials & Methods
- Microplate 384 well, small volume, black (Greiner, #784900)
- ThinSeal™ (ExcelScientiﬁc Inc., #100-THIN-PLT)
- CLARIOstar® plate reader, BMG LABTECH
- Acylated and biotinylated histone 3 derived peptides (LifeTein)
- Amyloid ﬁbrils2: RCM α-LA (100µM); in 20 mM sodium phosphate pH 7.4, 100 mM KCl, 10 mM MgCl2, 37°C, slow shaking. RCM ĸ-casein (50 μM); 20 mM sodium phosphate pH 7.4, 37 °C, 300 rpm. Insulin (200 μM); 50 mM glycine-HCl pH 2.0, 60 °C
- Dye concentration: 20µM; total volume: 20µL.
For FP experiments, TPE-TPP was pre-mixed with the proteins in solution prior to incubation at higher temperature. FP was recorded in situ with a CLARIOstar microplate reader and the settings indicated below. The background ﬂuorescence of TPE-TPP in the corresponding buffer solution under the respective protein ﬁbrillation conditions was subtracted, and the change in FP values was expressed in milli-polarization units (∆mP).
|Optic settings||Fluorescence Polarisation, plate mode kinetic|
|Filters||Ex: 360-20 |
|Gain||Channel A: 676 |
Channel B: 675
|Incubation||α-LA, k-casein 37 °C; insulin 60 °C|
|Shaking||α-LA: 100 rpm idle movement |
k-casein: 300 rpm idle movement
Results & Discussion
TPE-TPP exhibits emission characteristics that are aggregation-speciﬁc: it does not give a signal with stable molten globule states or amorphously aggregating species1. The compound can be used to monitor ﬁbril aggregation for various aggregating proteins under various conditions such as; acidic pH, elevated temperature and in the presence of amyloid inhibitors.1 Importantly, TPE-TPP can be used to monitor preﬁbrillar species via standard ﬂuorescence (data not shown) and FP.
Bovine insulin (monomeric mass 5.8 kDa) forms amyloid ﬁbrils at acidic pH (pH 2.0) and elevated temperature (60°C). Insulin exists as a dimer at acidic pH, which rapidly dissociates to monomer at higher temperature followed by a conformational change. The partially unfolded monomers associate with each other to form oligomeric intermediates including dimers, tetramers and hexamers.3 The FP study of the oligomerisation of monomers of bovine insulin, using TPE-TPP, clearly shows the progression from monomer to oligomers and then to insulin amyloid ﬁbril by the stepwise increase, each of around similar magnitude, in FP value (Fig 2).
RCM α-LA (monomeric mass 14.7 kDa) follows classical nucleation-dependent polymerization as apparent from its sigmoidal kinetic ﬂuorescence curve.4 Starting from monomers, soluble oligomers with increasing mass were formed after 2 h of incubation, as reﬂected by the steep increase of FP values. Rigid insoluble ﬁbrils were subsequently formed with FP reaching a maximum value and staying constant over the next 8 h (Fig 3a).
In contrast, RCM ĸ-casein (monomeric mass ~19 kDa) forms amyloid ﬁbrils via a different mechanism with the absence of a signiﬁcant lag phase. In solution at 25°C, RCM ĸ-casein occurs as a spherical particle with a weight average molecular mass of ~1180 kDa. Consistent with the difference in molecular mass, the FP of RCM ĸ-casein prior to incubation was higher than that of RCM α-LA (Fig 3b). At 37°C and neutral pH, RCM ĸ-casein assembles into ﬁbrillar structures.5 Amyloid ﬁbril formation by RCM ĸ-casein involves the dissociation of its spherical, oligomeric form into a monomeric amyloidogenic precursor, which then undergoes rapid aggregation to form a nucleus from which rigid, rod-like amyloid ﬁbrils develop.6
The results above clearly show that TPE-TPP-based FP measurements can monitor the ﬁbrillar assembly of a variety of amyloid ﬁbril-forming proteins in situ. In addition, the CLARIOstar multi-mode reader (BMG Labtech) is a versatile tool for these studies, offering temperature control to 65°C, heavy duty shaking, and high FP sensitivity.
1. Kumar, M. Hong, Y. et. al. Anal. Chem. 2017, 89, 9322–9329.
2. Kumar,M. Hong,Y.et al.1
3. Bekard, I. B.; Dunstan, D. E. Biophys. J. 2009, 97, 2521−2531.
4. Kulig, M.; Ecroyd, H. Biochem. J. 2012, 448, 343−352.
5. Thorn, D. C. et al. Biochemistry 2005, 44, 17027-17036.
6. Ecroyd, H. et al. J. Biol. Chem. 2008, 283, 9012-9022.